Wired News – Bruker Announces 10-Year Partnership with Metropolitan Museum of Art to Advance Novel Analytical Technologies

Stock Monitor: Analogic Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on Bruker Corp. (NASDAQ: BRKR), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=BRKR as the Company’s latest news hit the wire. On December 13, 2017, the Company announced that it has signed a 10-year partnership with the Metropolitan Museum of Art (“The Met”) to further advance novel analytical technologies and methods in the field of cultural heritage science. This partnership builds upon and expands a long history of collaboration that has yielded considerable progress and results. Sign up now for our free research report sat:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Bruker. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALOG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Bruker most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=BRKR

New Technologies Will Enable The Met’s Scientists to Advance Scholarship in Cultural Heritage Science

Through this partnership, both Companies plan to focus on advanced mass spectrometry instrumentation, x-ray diffraction, and Raman imaging, adding state-of-the-art technology to the impressive array of scientific tools already in place at The Met. The new technologies will enable The Met’s scientists to advance scholarship in cultural heritage science and solve the most challenging conservation problems.

Bruker will also offer instrumentation and technical expertise for the Network Initiative for Conservation Science (NICS), the new program established by The Met to support research at other museums in New York City. Bruker’s portable infrared, Raman, and x-ray fluorescence instrumentation operated by The Met’s scientists will play an essential role in establishing a mobile laboratory, and in building a distributed scientific network benefitting all cultural heritage institutions in the city of New York, and also to support the museums that lack scientific resources to perform in-depth chemical and elemental analysis.

Bruker and The Met Partnership Yielded New Instrumentation Development

The Companies have been working together for a long time, and their association has yielded new instrumentation development and methods that are now commonly used around the world. In August 2009, The Met carried out FT-Raman spectroscopy using a Bruker Ram II FT-Raman-Vertex 70 FTIR Micro spectrometer. The 1064 nm line of an Nd:YAG laser used as the excitation line. Additional SERS work on Ag colloids was carried out using a Bruker Senterra Raman microscope.

In October 2013, a series of paintings of The Met were analyzed by means of the Bruker M6 MA-XRF instrument. The Bruker M6 JETSTREAM is designed for the non-destructive elemental analysis of large samples. The mobility of the instrument allows it to be placed at the site of the object of interest. The performance parameters enable scanning areas of 800 mm x 600 mm, with a variable spot size down to 100 µm and speeds of up to 100 mm/s.

About Metropolitan Museum of Art (The Met)

Established in 1870 and based in New York, The Met is the largest art museum in the United States, and presents over 5,000 years of art from around the world. The Department of Scientific Research at The Met is responsible for investigating the material aspects of works of art in the collection. Scientists in the department cooperate with conservators and curators in studying, preserving, and conserving the works, and also pursue innovative research in analytical techniques, preventive conservation, and treatment methodologies.

About Bruker Corp.

Founded in 1960, Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. The Company’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. Bruker is headquartered in Billerica, Massachusetts.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, Bruker’s stock slightly fell 0.85%, ending the trading session at $33.90.

Volume traded for the day: 373.48 thousand shares.

Stock performance in the last month – up 3.70%; previous three-month period – up 13.57%; past twelve-month period – up 60.13%; and year-to-date – up 60.06%

After yesterday’s close, Bruker’s market cap was at $5.18 billion.

Price to Earnings (P/E) ratio was at 35.95.

The stock has a dividend yield of 0.47%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors